Encompass Health (NYSE:EHC) PT Raised to $113.00 at Barclays

Encompass Health (NYSE:EHC) had its price target hoisted by Barclays from $108.00 to $113.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price target suggests a potential upside of 33.30% from the company’s previous close.

Other equities analysts also recently issued reports about the company. SVB Leerink started coverage on Encompass Health in a report on Wednesday. They set an “outperform” rating and a $100.00 price target for the company. Raymond James reiterated a “strong-buy” rating and issued a $95.00 price objective (up from $85.00) on shares of Encompass Health in a report on Friday, April 26th. Stephens reiterated an “overweight” rating and issued a $94.00 price objective on shares of Encompass Health in a report on Wednesday, June 5th. Royal Bank of Canada lifted their price objective on Encompass Health from $83.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, May 22nd. Finally, Mizuho lifted their price objective on Encompass Health from $93.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Nine investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $94.75.

Encompass Health Stock Performance

Shares of Encompass Health stock opened at $84.77 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.14. The firm has a market capitalization of $8.54 billion, a P/E ratio of 22.91, a P/E/G ratio of 1.31 and a beta of 0.89. The business has a fifty day simple moving average of $85.18 and a two-hundred day simple moving average of $78.55. Encompass Health has a 12 month low of $57.55 and a 12 month high of $87.94.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.19. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.27 billion. During the same period last year, the company earned $0.88 earnings per share. The company’s revenue was up 13.4% on a year-over-year basis. On average, equities analysts forecast that Encompass Health will post 4.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Mark J. Tarr sold 44,976 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the transaction, the chief executive officer now owns 554,098 shares of the company’s stock, valued at approximately $46,139,740.46. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Encompass Health news, insider Elissa Joy Charbonneau sold 10,000 shares of the business’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $85.02, for a total value of $850,200.00. Following the completion of the sale, the insider now directly owns 18,594 shares of the company’s stock, valued at approximately $1,580,861.88. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Mark J. Tarr sold 44,976 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the completion of the sale, the chief executive officer now directly owns 554,098 shares of the company’s stock, valued at $46,139,740.46. The disclosure for this sale can be found here. Insiders have sold a total of 69,519 shares of company stock valued at $5,816,091 in the last quarter. 2.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Encompass Health

Several large investors have recently added to or reduced their stakes in EHC. Principal Securities Inc. bought a new stake in shares of Encompass Health in the 4th quarter valued at about $25,000. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Encompass Health by 360.2% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company’s stock valued at $27,000 after purchasing an additional 317 shares in the last quarter. McGlone Suttner Wealth Management Inc. bought a new stake in shares of Encompass Health in the 4th quarter valued at about $30,000. GAMMA Investing LLC bought a new stake in shares of Encompass Health in the 4th quarter valued at about $33,000. Finally, Parallel Advisors LLC raised its holdings in shares of Encompass Health by 192.3% in the 4th quarter. Parallel Advisors LLC now owns 573 shares of the company’s stock valued at $38,000 after purchasing an additional 377 shares in the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.